Neoadjuvant Chemotherapy for Pancreatic Cancer; GS vs. GnP

Kochi University1 site in 1 country500 target enrollmentJanuary 1, 2019

ConditionsPancreatic Adenocarcinoma

InterventionsGS GnP

DrugsGS GnP

Overview

Phase: Phase 2
Intervention: GS
Conditions: Pancreatic Adenocarcinoma
Sponsor: Kochi University
Enrollment: 500
Locations: 1
Primary Endpoint: overall survival
Status: Recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.

Detailed Description

gemcitabine plus S-1 versus gemcitabine plus nab-paclitaxel

Registry

clinicaltrials.gov

Start Date

January 1, 2019

End Date

December 31, 2030

Last Updated

4 years ago

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

Kochi University

Responsible Party

Principal Investigator

Takehiro Okabayashi

Department of Surgery

Kochi University

Eligibility Criteria

Inclusion Criteria

•elective pancreatectomy for pancreatic cancer

Exclusion Criteria

•a previous cancer surgery a body weight loss of \>10% during the 6 months before surgery the presence of distant metastases seriously impaired function of vital organs because of respiratory, renal, or heart disease.